Compare Regeneron Pharmaceuticals Inc (REGN) vs Zeta Global Holdings Corp (ZETA) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.

The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.

ZETA trades at $30.79, down 1.79% today but near its consensus price target of $31.19. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $1.3B in 2025 with a gross margin of 59.48%, though net income remains negative. Positive sentiment is driven by AI platform growth and institutional interest, with the stock up 51% year-to-date according to FXEmpire on September 9, 2026.

Outlook remains positive given analyst consensus (75% buy ratings) and accelerating business performance, but risks include rich valuation (P/S 4.54, EV/EBITDA 100.13) and execution challenges in maintaining growth momentum. Negative cash flow and slim margins require monitoring as the company scales.